logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
6/17/2019 7:11:00 AM Protalix BioTherapeutics Completes Enrollment In Phase III BRIGHT Clinical Trial Of PRX 102 For Fabry Disease
3/18/2019 6:57:21 AM Protalix FY Net Loss $26.5 Mln Or $0.18 Per Share
1/28/2019 7:03:57 AM Protalix BioTherapeutics To Present Preliminary Data From The BRIGHT Study Of Pegunigalsidase Alfa For Fabry Disease
12/17/2018 7:01:33 AM Protalix BioTherapeutics Completes Enrollment In Phase III BRIDGE Clinical Trial Of Pegunigalsidase Alfa
11/7/2018 7:01:07 AM Protalix BioTherapeutics Q3 Loss Per Share $0.10 Vs Loss $0.09 Last Year
10/5/2018 7:18:36 AM Protalix BioTherapeutics Presents Positive Preliminary Data From BRIDGE Study Of Pegunigalsidase Alfa
9/21/2018 10:58:57 AM Protalix Reports Positive Preliminary Data From BRIDGE Study Of Pegunigalsidase Alfa For Treatment Of Fabry Disease
9/17/2018 7:01:54 AM Protalix BioTherapeutics To Present Preliminary Data From BRIDGE Study Of Pegunigalsidase Alfa
8/13/2018 7:01:45 AM Protalix BioTherapeutics Appoints David Granot To Board
8/9/2018 7:02:57 AM Protalix BioTherapeutics Q2 Loss Per Share $0.08 Vs Loss $0.06 Last Year
7/24/2018 7:03:24 AM Protalix BioTherapeutics Expands Partnership With Chiesi Farmaceutici For Commercialization Of PRX-102
6/5/2018 7:02:13 AM Protalix BioTherapeutics Announces Addl Positive Results From Final Analysis Of Phase II Clinical Trial Of OPRX-106